nodes	percent_of_prediction	percent_of_DWPC	metapath
Everolimus—kidney cancer—liver cancer	0.482	1	CtDrD
Everolimus—MTOR—liver cancer	0.374	1	CbGaD
Everolimus—Pimecrolimus—MTOR—liver cancer	0.00114	0.336	CrCbGaD
Everolimus—Temsirolimus—MTOR—liver cancer	0.000773	0.227	CrCbGaD
Everolimus—Tacrolimus—MTOR—liver cancer	0.000681	0.2	CrCbGaD
Everolimus—Sirolimus—MTOR—liver cancer	0.000681	0.2	CrCbGaD
Everolimus—Tacrolimus—ALB—liver cancer	0.000123	0.036	CrCbGaD
Everolimus—Renal impairment—Doxorubicin—liver cancer	8.58e-05	0.00111	CcSEcCtD
Everolimus—Asthenia—Sorafenib—liver cancer	8.43e-05	0.00109	CcSEcCtD
Everolimus—Cardiac arrest—Epirubicin—liver cancer	8.4e-05	0.00109	CcSEcCtD
Everolimus—Hypoglycaemia—Doxorubicin—liver cancer	8.37e-05	0.00108	CcSEcCtD
Everolimus—Cardiac failure—Doxorubicin—liver cancer	8.37e-05	0.00108	CcSEcCtD
Everolimus—Lethargy—Doxorubicin—liver cancer	8.34e-05	0.00108	CcSEcCtD
Everolimus—Pruritus—Sorafenib—liver cancer	8.31e-05	0.00108	CcSEcCtD
Everolimus—Blood creatinine increased—Epirubicin—liver cancer	8.27e-05	0.00107	CcSEcCtD
Everolimus—Dehydration—Epirubicin—liver cancer	8.21e-05	0.00106	CcSEcCtD
Everolimus—Hyponatraemia—Doxorubicin—liver cancer	8.2e-05	0.00106	CcSEcCtD
Everolimus—Pain in extremity—Doxorubicin—liver cancer	8.17e-05	0.00106	CcSEcCtD
Everolimus—Liver function test abnormal—Epirubicin—liver cancer	8.15e-05	0.00105	CcSEcCtD
Everolimus—Dry skin—Epirubicin—liver cancer	8.09e-05	0.00105	CcSEcCtD
Everolimus—Abdominal pain upper—Epirubicin—liver cancer	8.06e-05	0.00104	CcSEcCtD
Everolimus—Migraine—Doxorubicin—liver cancer	8.04e-05	0.00104	CcSEcCtD
Everolimus—Hypokalaemia—Epirubicin—liver cancer	8.04e-05	0.00104	CcSEcCtD
Everolimus—Diarrhoea—Sorafenib—liver cancer	8.03e-05	0.00104	CcSEcCtD
Everolimus—Breast disorder—Epirubicin—liver cancer	7.98e-05	0.00103	CcSEcCtD
Everolimus—Aspartate aminotransferase increased—Epirubicin—liver cancer	7.95e-05	0.00103	CcSEcCtD
Everolimus—Nasopharyngitis—Epirubicin—liver cancer	7.9e-05	0.00102	CcSEcCtD
Everolimus—Gastritis—Epirubicin—liver cancer	7.81e-05	0.00101	CcSEcCtD
Everolimus—Muscular weakness—Epirubicin—liver cancer	7.79e-05	0.00101	CcSEcCtD
Everolimus—Alanine aminotransferase increased—Epirubicin—liver cancer	7.79e-05	0.00101	CcSEcCtD
Everolimus—Cardiac arrest—Doxorubicin—liver cancer	7.77e-05	0.00101	CcSEcCtD
Everolimus—Dizziness—Sorafenib—liver cancer	7.77e-05	0.001	CcSEcCtD
Everolimus—Abdominal distension—Epirubicin—liver cancer	7.68e-05	0.000994	CcSEcCtD
Everolimus—Blood creatinine increased—Doxorubicin—liver cancer	7.65e-05	0.00099	CcSEcCtD
Everolimus—Dysphagia—Epirubicin—liver cancer	7.63e-05	0.000988	CcSEcCtD
Everolimus—Influenza—Epirubicin—liver cancer	7.63e-05	0.000988	CcSEcCtD
Everolimus—Dehydration—Doxorubicin—liver cancer	7.6e-05	0.000983	CcSEcCtD
Everolimus—Liver function test abnormal—Doxorubicin—liver cancer	7.54e-05	0.000976	CcSEcCtD
Everolimus—Dry skin—Doxorubicin—liver cancer	7.49e-05	0.000969	CcSEcCtD
Everolimus—Pancreatitis—Epirubicin—liver cancer	7.48e-05	0.000968	CcSEcCtD
Everolimus—Vomiting—Sorafenib—liver cancer	7.47e-05	0.000966	CcSEcCtD
Everolimus—Abdominal pain upper—Doxorubicin—liver cancer	7.46e-05	0.000966	CcSEcCtD
Everolimus—Hypokalaemia—Doxorubicin—liver cancer	7.44e-05	0.000962	CcSEcCtD
Everolimus—Angina pectoris—Epirubicin—liver cancer	7.43e-05	0.000962	CcSEcCtD
Everolimus—Rash—Sorafenib—liver cancer	7.4e-05	0.000958	CcSEcCtD
Everolimus—Dermatitis—Sorafenib—liver cancer	7.4e-05	0.000957	CcSEcCtD
Everolimus—Breast disorder—Doxorubicin—liver cancer	7.38e-05	0.000955	CcSEcCtD
Everolimus—Aspartate aminotransferase increased—Doxorubicin—liver cancer	7.36e-05	0.000952	CcSEcCtD
Everolimus—Headache—Sorafenib—liver cancer	7.36e-05	0.000952	CcSEcCtD
Everolimus—Bronchitis—Epirubicin—liver cancer	7.34e-05	0.00095	CcSEcCtD
Everolimus—Nasopharyngitis—Doxorubicin—liver cancer	7.31e-05	0.000945	CcSEcCtD
Everolimus—Pancytopenia—Epirubicin—liver cancer	7.25e-05	0.000938	CcSEcCtD
Everolimus—Gastritis—Doxorubicin—liver cancer	7.23e-05	0.000936	CcSEcCtD
Everolimus—Muscular weakness—Doxorubicin—liver cancer	7.21e-05	0.000932	CcSEcCtD
Everolimus—Alanine aminotransferase increased—Doxorubicin—liver cancer	7.21e-05	0.000932	CcSEcCtD
Everolimus—Dysuria—Epirubicin—liver cancer	7.14e-05	0.000923	CcSEcCtD
Everolimus—Neutropenia—Epirubicin—liver cancer	7.14e-05	0.000923	CcSEcCtD
Everolimus—Abdominal distension—Doxorubicin—liver cancer	7.11e-05	0.00092	CcSEcCtD
Everolimus—Upper respiratory tract infection—Epirubicin—liver cancer	7.09e-05	0.000918	CcSEcCtD
Everolimus—Influenza—Doxorubicin—liver cancer	7.06e-05	0.000914	CcSEcCtD
Everolimus—Dysphagia—Doxorubicin—liver cancer	7.06e-05	0.000914	CcSEcCtD
Everolimus—Pollakiuria—Epirubicin—liver cancer	7.05e-05	0.000912	CcSEcCtD
Everolimus—Nausea—Sorafenib—liver cancer	6.98e-05	0.000903	CcSEcCtD
Everolimus—Pancreatitis—Doxorubicin—liver cancer	6.92e-05	0.000896	CcSEcCtD
Everolimus—Weight decreased—Epirubicin—liver cancer	6.9e-05	0.000893	CcSEcCtD
Everolimus—Hyperglycaemia—Epirubicin—liver cancer	6.88e-05	0.000891	CcSEcCtD
Everolimus—Angina pectoris—Doxorubicin—liver cancer	6.88e-05	0.00089	CcSEcCtD
Everolimus—Pneumonia—Epirubicin—liver cancer	6.84e-05	0.000886	CcSEcCtD
Everolimus—Infestation NOS—Epirubicin—liver cancer	6.8e-05	0.000881	CcSEcCtD
Everolimus—Infestation—Epirubicin—liver cancer	6.8e-05	0.000881	CcSEcCtD
Everolimus—Bronchitis—Doxorubicin—liver cancer	6.79e-05	0.000879	CcSEcCtD
Everolimus—Pancytopenia—Doxorubicin—liver cancer	6.71e-05	0.000868	CcSEcCtD
Everolimus—Renal failure—Epirubicin—liver cancer	6.69e-05	0.000866	CcSEcCtD
Everolimus—Stomatitis—Epirubicin—liver cancer	6.63e-05	0.000858	CcSEcCtD
Everolimus—Jaundice—Epirubicin—liver cancer	6.63e-05	0.000858	CcSEcCtD
Everolimus—Conjunctivitis—Epirubicin—liver cancer	6.61e-05	0.000856	CcSEcCtD
Everolimus—Urinary tract infection—Epirubicin—liver cancer	6.61e-05	0.000856	CcSEcCtD
Everolimus—Neutropenia—Doxorubicin—liver cancer	6.6e-05	0.000854	CcSEcCtD
Everolimus—Dysuria—Doxorubicin—liver cancer	6.6e-05	0.000854	CcSEcCtD
Everolimus—Upper respiratory tract infection—Doxorubicin—liver cancer	6.56e-05	0.000849	CcSEcCtD
Everolimus—Pollakiuria—Doxorubicin—liver cancer	6.52e-05	0.000844	CcSEcCtD
Everolimus—Haematuria—Epirubicin—liver cancer	6.49e-05	0.00084	CcSEcCtD
Everolimus—Hepatobiliary disease—Epirubicin—liver cancer	6.44e-05	0.000833	CcSEcCtD
Everolimus—Epistaxis—Epirubicin—liver cancer	6.42e-05	0.000831	CcSEcCtD
Everolimus—Weight decreased—Doxorubicin—liver cancer	6.39e-05	0.000827	CcSEcCtD
Everolimus—Sinusitis—Epirubicin—liver cancer	6.38e-05	0.000826	CcSEcCtD
Everolimus—Hyperglycaemia—Doxorubicin—liver cancer	6.37e-05	0.000824	CcSEcCtD
Everolimus—Pneumonia—Doxorubicin—liver cancer	6.33e-05	0.000819	CcSEcCtD
Everolimus—Infestation NOS—Doxorubicin—liver cancer	6.3e-05	0.000815	CcSEcCtD
Everolimus—Infestation—Doxorubicin—liver cancer	6.3e-05	0.000815	CcSEcCtD
Everolimus—Renal failure—Doxorubicin—liver cancer	6.19e-05	0.000801	CcSEcCtD
Everolimus—Haemoglobin—Epirubicin—liver cancer	6.14e-05	0.000794	CcSEcCtD
Everolimus—Stomatitis—Doxorubicin—liver cancer	6.14e-05	0.000794	CcSEcCtD
Everolimus—Jaundice—Doxorubicin—liver cancer	6.14e-05	0.000794	CcSEcCtD
Everolimus—Rhinitis—Epirubicin—liver cancer	6.12e-05	0.000792	CcSEcCtD
Everolimus—Urinary tract infection—Doxorubicin—liver cancer	6.12e-05	0.000792	CcSEcCtD
Everolimus—Conjunctivitis—Doxorubicin—liver cancer	6.12e-05	0.000792	CcSEcCtD
Everolimus—Haemorrhage—Epirubicin—liver cancer	6.11e-05	0.00079	CcSEcCtD
Everolimus—Hepatitis—Epirubicin—liver cancer	6.11e-05	0.00079	CcSEcCtD
Everolimus—Hypoaesthesia—Epirubicin—liver cancer	6.08e-05	0.000786	CcSEcCtD
Everolimus—Pharyngitis—Epirubicin—liver cancer	6.06e-05	0.000785	CcSEcCtD
Everolimus—Urinary tract disorder—Epirubicin—liver cancer	6.03e-05	0.000781	CcSEcCtD
Everolimus—Oedema peripheral—Epirubicin—liver cancer	6.02e-05	0.000779	CcSEcCtD
Everolimus—Haematuria—Doxorubicin—liver cancer	6e-05	0.000777	CcSEcCtD
Everolimus—Connective tissue disorder—Epirubicin—liver cancer	6e-05	0.000777	CcSEcCtD
Everolimus—Urethral disorder—Epirubicin—liver cancer	5.99e-05	0.000775	CcSEcCtD
Everolimus—Hepatobiliary disease—Doxorubicin—liver cancer	5.95e-05	0.000771	CcSEcCtD
Everolimus—Epistaxis—Doxorubicin—liver cancer	5.94e-05	0.000768	CcSEcCtD
Everolimus—Sinusitis—Doxorubicin—liver cancer	5.91e-05	0.000764	CcSEcCtD
Everolimus—Eye disorder—Epirubicin—liver cancer	5.71e-05	0.000739	CcSEcCtD
Everolimus—Haemoglobin—Doxorubicin—liver cancer	5.68e-05	0.000735	CcSEcCtD
Everolimus—Cardiac disorder—Epirubicin—liver cancer	5.67e-05	0.000734	CcSEcCtD
Everolimus—Flushing—Epirubicin—liver cancer	5.67e-05	0.000734	CcSEcCtD
Everolimus—Rhinitis—Doxorubicin—liver cancer	5.67e-05	0.000733	CcSEcCtD
Everolimus—Haemorrhage—Doxorubicin—liver cancer	5.65e-05	0.000731	CcSEcCtD
Everolimus—Hepatitis—Doxorubicin—liver cancer	5.65e-05	0.000731	CcSEcCtD
Everolimus—Hypoaesthesia—Doxorubicin—liver cancer	5.62e-05	0.000728	CcSEcCtD
Everolimus—Pharyngitis—Doxorubicin—liver cancer	5.61e-05	0.000726	CcSEcCtD
Everolimus—Urinary tract disorder—Doxorubicin—liver cancer	5.58e-05	0.000722	CcSEcCtD
Everolimus—Oedema peripheral—Doxorubicin—liver cancer	5.57e-05	0.00072	CcSEcCtD
Everolimus—Connective tissue disorder—Doxorubicin—liver cancer	5.55e-05	0.000719	CcSEcCtD
Everolimus—Angiopathy—Epirubicin—liver cancer	5.54e-05	0.000717	CcSEcCtD
Everolimus—Urethral disorder—Doxorubicin—liver cancer	5.54e-05	0.000717	CcSEcCtD
Everolimus—Immune system disorder—Epirubicin—liver cancer	5.52e-05	0.000714	CcSEcCtD
Everolimus—Mediastinal disorder—Epirubicin—liver cancer	5.51e-05	0.000712	CcSEcCtD
Everolimus—Chills—Epirubicin—liver cancer	5.48e-05	0.000709	CcSEcCtD
Everolimus—Alopecia—Epirubicin—liver cancer	5.4e-05	0.000698	CcSEcCtD
Everolimus—Mental disorder—Epirubicin—liver cancer	5.35e-05	0.000692	CcSEcCtD
Everolimus—Malnutrition—Epirubicin—liver cancer	5.32e-05	0.000688	CcSEcCtD
Everolimus—Erythema—Epirubicin—liver cancer	5.32e-05	0.000688	CcSEcCtD
Everolimus—Eye disorder—Doxorubicin—liver cancer	5.28e-05	0.000683	CcSEcCtD
Everolimus—Cardiac disorder—Doxorubicin—liver cancer	5.25e-05	0.000679	CcSEcCtD
Everolimus—Flushing—Doxorubicin—liver cancer	5.25e-05	0.000679	CcSEcCtD
Everolimus—Flatulence—Epirubicin—liver cancer	5.24e-05	0.000678	CcSEcCtD
Everolimus—Dysgeusia—Epirubicin—liver cancer	5.21e-05	0.000674	CcSEcCtD
Everolimus—Back pain—Epirubicin—liver cancer	5.14e-05	0.000666	CcSEcCtD
Everolimus—Angiopathy—Doxorubicin—liver cancer	5.13e-05	0.000664	CcSEcCtD
Everolimus—Muscle spasms—Epirubicin—liver cancer	5.11e-05	0.000662	CcSEcCtD
Everolimus—Immune system disorder—Doxorubicin—liver cancer	5.11e-05	0.000661	CcSEcCtD
Everolimus—Mediastinal disorder—Doxorubicin—liver cancer	5.09e-05	0.000659	CcSEcCtD
Everolimus—Chills—Doxorubicin—liver cancer	5.07e-05	0.000656	CcSEcCtD
Everolimus—Vision blurred—Epirubicin—liver cancer	5.01e-05	0.000648	CcSEcCtD
Everolimus—Alopecia—Doxorubicin—liver cancer	4.99e-05	0.000646	CcSEcCtD
Everolimus—Mental disorder—Doxorubicin—liver cancer	4.95e-05	0.000641	CcSEcCtD
Everolimus—Ill-defined disorder—Epirubicin—liver cancer	4.93e-05	0.000638	CcSEcCtD
Everolimus—Erythema—Doxorubicin—liver cancer	4.92e-05	0.000637	CcSEcCtD
Everolimus—Malnutrition—Doxorubicin—liver cancer	4.92e-05	0.000637	CcSEcCtD
Everolimus—Anaemia—Epirubicin—liver cancer	4.91e-05	0.000636	CcSEcCtD
Everolimus—Agitation—Epirubicin—liver cancer	4.89e-05	0.000632	CcSEcCtD
Everolimus—Flatulence—Doxorubicin—liver cancer	4.85e-05	0.000627	CcSEcCtD
Everolimus—Dysgeusia—Doxorubicin—liver cancer	4.82e-05	0.000623	CcSEcCtD
Everolimus—Malaise—Epirubicin—liver cancer	4.8e-05	0.000621	CcSEcCtD
Everolimus—Syncope—Epirubicin—liver cancer	4.77e-05	0.000617	CcSEcCtD
Everolimus—Leukopenia—Epirubicin—liver cancer	4.76e-05	0.000616	CcSEcCtD
Everolimus—Back pain—Doxorubicin—liver cancer	4.76e-05	0.000616	CcSEcCtD
Everolimus—Muscle spasms—Doxorubicin—liver cancer	4.73e-05	0.000612	CcSEcCtD
Everolimus—Palpitations—Epirubicin—liver cancer	4.7e-05	0.000608	CcSEcCtD
Everolimus—Loss of consciousness—Epirubicin—liver cancer	4.67e-05	0.000605	CcSEcCtD
Everolimus—Cough—Epirubicin—liver cancer	4.64e-05	0.0006	CcSEcCtD
Everolimus—Vision blurred—Doxorubicin—liver cancer	4.64e-05	0.0006	CcSEcCtD
Everolimus—Convulsion—Epirubicin—liver cancer	4.61e-05	0.000596	CcSEcCtD
Everolimus—Hypertension—Epirubicin—liver cancer	4.59e-05	0.000594	CcSEcCtD
Everolimus—Ill-defined disorder—Doxorubicin—liver cancer	4.57e-05	0.000591	CcSEcCtD
Everolimus—Anaemia—Doxorubicin—liver cancer	4.55e-05	0.000588	CcSEcCtD
Everolimus—Chest pain—Epirubicin—liver cancer	4.53e-05	0.000586	CcSEcCtD
Everolimus—Arthralgia—Epirubicin—liver cancer	4.53e-05	0.000586	CcSEcCtD
Everolimus—Myalgia—Epirubicin—liver cancer	4.53e-05	0.000586	CcSEcCtD
Everolimus—Agitation—Doxorubicin—liver cancer	4.52e-05	0.000585	CcSEcCtD
Everolimus—Anxiety—Epirubicin—liver cancer	4.51e-05	0.000584	CcSEcCtD
Everolimus—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—liver cancer	4.5e-05	0.000582	CcSEcCtD
Everolimus—Discomfort—Epirubicin—liver cancer	4.47e-05	0.000579	CcSEcCtD
Everolimus—Malaise—Doxorubicin—liver cancer	4.44e-05	0.000574	CcSEcCtD
Everolimus—Dry mouth—Epirubicin—liver cancer	4.43e-05	0.000573	CcSEcCtD
Everolimus—Syncope—Doxorubicin—liver cancer	4.41e-05	0.000571	CcSEcCtD
Everolimus—Leukopenia—Doxorubicin—liver cancer	4.4e-05	0.00057	CcSEcCtD
Everolimus—Palpitations—Doxorubicin—liver cancer	4.35e-05	0.000563	CcSEcCtD
Everolimus—Oedema—Epirubicin—liver cancer	4.34e-05	0.000562	CcSEcCtD
Everolimus—Loss of consciousness—Doxorubicin—liver cancer	4.32e-05	0.00056	CcSEcCtD
Everolimus—Infection—Epirubicin—liver cancer	4.31e-05	0.000558	CcSEcCtD
Everolimus—Cough—Doxorubicin—liver cancer	4.29e-05	0.000556	CcSEcCtD
Everolimus—Shock—Epirubicin—liver cancer	4.27e-05	0.000552	CcSEcCtD
Everolimus—Convulsion—Doxorubicin—liver cancer	4.26e-05	0.000552	CcSEcCtD
Everolimus—Nervous system disorder—Epirubicin—liver cancer	4.26e-05	0.000551	CcSEcCtD
Everolimus—Thrombocytopenia—Epirubicin—liver cancer	4.25e-05	0.00055	CcSEcCtD
Everolimus—Hypertension—Doxorubicin—liver cancer	4.25e-05	0.00055	CcSEcCtD
Everolimus—Tachycardia—Epirubicin—liver cancer	4.24e-05	0.000548	CcSEcCtD
Everolimus—Skin disorder—Epirubicin—liver cancer	4.22e-05	0.000545	CcSEcCtD
Everolimus—Hyperhidrosis—Epirubicin—liver cancer	4.2e-05	0.000543	CcSEcCtD
Everolimus—Chest pain—Doxorubicin—liver cancer	4.19e-05	0.000542	CcSEcCtD
Everolimus—Arthralgia—Doxorubicin—liver cancer	4.19e-05	0.000542	CcSEcCtD
Everolimus—Myalgia—Doxorubicin—liver cancer	4.19e-05	0.000542	CcSEcCtD
Everolimus—Anxiety—Doxorubicin—liver cancer	4.17e-05	0.00054	CcSEcCtD
Everolimus—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—liver cancer	4.16e-05	0.000538	CcSEcCtD
Everolimus—Discomfort—Doxorubicin—liver cancer	4.14e-05	0.000536	CcSEcCtD
Everolimus—Anorexia—Epirubicin—liver cancer	4.14e-05	0.000535	CcSEcCtD
Everolimus—Dry mouth—Doxorubicin—liver cancer	4.1e-05	0.00053	CcSEcCtD
Everolimus—Hypotension—Epirubicin—liver cancer	4.06e-05	0.000525	CcSEcCtD
Everolimus—Oedema—Doxorubicin—liver cancer	4.02e-05	0.00052	CcSEcCtD
Everolimus—Infection—Doxorubicin—liver cancer	3.99e-05	0.000516	CcSEcCtD
Everolimus—Musculoskeletal discomfort—Epirubicin—liver cancer	3.95e-05	0.000512	CcSEcCtD
Everolimus—Shock—Doxorubicin—liver cancer	3.95e-05	0.000511	CcSEcCtD
Everolimus—Nervous system disorder—Doxorubicin—liver cancer	3.94e-05	0.00051	CcSEcCtD
Everolimus—Thrombocytopenia—Doxorubicin—liver cancer	3.93e-05	0.000509	CcSEcCtD
Everolimus—Insomnia—Epirubicin—liver cancer	3.93e-05	0.000508	CcSEcCtD
Everolimus—Tachycardia—Doxorubicin—liver cancer	3.92e-05	0.000507	CcSEcCtD
Everolimus—Skin disorder—Doxorubicin—liver cancer	3.9e-05	0.000505	CcSEcCtD
Everolimus—Paraesthesia—Epirubicin—liver cancer	3.9e-05	0.000504	CcSEcCtD
Everolimus—Hyperhidrosis—Doxorubicin—liver cancer	3.88e-05	0.000502	CcSEcCtD
Everolimus—Dyspnoea—Epirubicin—liver cancer	3.87e-05	0.000501	CcSEcCtD
Everolimus—Somnolence—Epirubicin—liver cancer	3.86e-05	0.000499	CcSEcCtD
Everolimus—Anorexia—Doxorubicin—liver cancer	3.83e-05	0.000495	CcSEcCtD
Everolimus—Dyspepsia—Epirubicin—liver cancer	3.82e-05	0.000494	CcSEcCtD
Everolimus—Decreased appetite—Epirubicin—liver cancer	3.77e-05	0.000488	CcSEcCtD
Everolimus—Hypotension—Doxorubicin—liver cancer	3.75e-05	0.000486	CcSEcCtD
Everolimus—Gastrointestinal disorder—Epirubicin—liver cancer	3.75e-05	0.000485	CcSEcCtD
Everolimus—Fatigue—Epirubicin—liver cancer	3.74e-05	0.000484	CcSEcCtD
Everolimus—Constipation—Epirubicin—liver cancer	3.71e-05	0.00048	CcSEcCtD
Everolimus—Pain—Epirubicin—liver cancer	3.71e-05	0.00048	CcSEcCtD
Everolimus—Musculoskeletal discomfort—Doxorubicin—liver cancer	3.66e-05	0.000473	CcSEcCtD
Everolimus—Insomnia—Doxorubicin—liver cancer	3.63e-05	0.00047	CcSEcCtD
Everolimus—Paraesthesia—Doxorubicin—liver cancer	3.61e-05	0.000467	CcSEcCtD
Everolimus—Dyspnoea—Doxorubicin—liver cancer	3.58e-05	0.000463	CcSEcCtD
Everolimus—Feeling abnormal—Epirubicin—liver cancer	3.58e-05	0.000463	CcSEcCtD
Everolimus—Somnolence—Doxorubicin—liver cancer	3.57e-05	0.000462	CcSEcCtD
Everolimus—Gastrointestinal pain—Epirubicin—liver cancer	3.55e-05	0.000459	CcSEcCtD
Everolimus—Dyspepsia—Doxorubicin—liver cancer	3.53e-05	0.000457	CcSEcCtD
Everolimus—Decreased appetite—Doxorubicin—liver cancer	3.49e-05	0.000452	CcSEcCtD
Everolimus—Gastrointestinal disorder—Doxorubicin—liver cancer	3.47e-05	0.000449	CcSEcCtD
Everolimus—Fatigue—Doxorubicin—liver cancer	3.46e-05	0.000448	CcSEcCtD
Everolimus—Constipation—Doxorubicin—liver cancer	3.43e-05	0.000444	CcSEcCtD
Everolimus—Pain—Doxorubicin—liver cancer	3.43e-05	0.000444	CcSEcCtD
Everolimus—Abdominal pain—Epirubicin—liver cancer	3.43e-05	0.000444	CcSEcCtD
Everolimus—Body temperature increased—Epirubicin—liver cancer	3.43e-05	0.000444	CcSEcCtD
Everolimus—Feeling abnormal—Doxorubicin—liver cancer	3.31e-05	0.000428	CcSEcCtD
Everolimus—Gastrointestinal pain—Doxorubicin—liver cancer	3.28e-05	0.000425	CcSEcCtD
Everolimus—Hypersensitivity—Epirubicin—liver cancer	3.2e-05	0.000414	CcSEcCtD
Everolimus—Abdominal pain—Doxorubicin—liver cancer	3.17e-05	0.000411	CcSEcCtD
Everolimus—Body temperature increased—Doxorubicin—liver cancer	3.17e-05	0.000411	CcSEcCtD
Everolimus—Asthenia—Epirubicin—liver cancer	3.11e-05	0.000403	CcSEcCtD
Everolimus—Pruritus—Epirubicin—liver cancer	3.07e-05	0.000397	CcSEcCtD
Everolimus—Diarrhoea—Epirubicin—liver cancer	2.97e-05	0.000384	CcSEcCtD
Everolimus—Hypersensitivity—Doxorubicin—liver cancer	2.96e-05	0.000383	CcSEcCtD
Everolimus—Asthenia—Doxorubicin—liver cancer	2.88e-05	0.000373	CcSEcCtD
Everolimus—Dizziness—Epirubicin—liver cancer	2.87e-05	0.000371	CcSEcCtD
Everolimus—Pruritus—Doxorubicin—liver cancer	2.84e-05	0.000368	CcSEcCtD
Everolimus—Vomiting—Epirubicin—liver cancer	2.76e-05	0.000357	CcSEcCtD
Everolimus—Diarrhoea—Doxorubicin—liver cancer	2.75e-05	0.000356	CcSEcCtD
Everolimus—Rash—Epirubicin—liver cancer	2.74e-05	0.000354	CcSEcCtD
Everolimus—Dermatitis—Epirubicin—liver cancer	2.73e-05	0.000354	CcSEcCtD
Everolimus—Headache—Epirubicin—liver cancer	2.72e-05	0.000352	CcSEcCtD
Everolimus—Dizziness—Doxorubicin—liver cancer	2.66e-05	0.000344	CcSEcCtD
Everolimus—Nausea—Epirubicin—liver cancer	2.58e-05	0.000334	CcSEcCtD
Everolimus—Vomiting—Doxorubicin—liver cancer	2.55e-05	0.00033	CcSEcCtD
Everolimus—Rash—Doxorubicin—liver cancer	2.53e-05	0.000328	CcSEcCtD
Everolimus—Dermatitis—Doxorubicin—liver cancer	2.53e-05	0.000327	CcSEcCtD
Everolimus—Headache—Doxorubicin—liver cancer	2.52e-05	0.000326	CcSEcCtD
Everolimus—Nausea—Doxorubicin—liver cancer	2.39e-05	0.000309	CcSEcCtD
Everolimus—MTOR—Fc epsilon receptor (FCERI) signaling—HRAS—liver cancer	1.95e-05	0.000312	CbGpPWpGaD
Everolimus—MTOR—DAP12 interactions—HRAS—liver cancer	1.95e-05	0.000312	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR in disease—HRAS—liver cancer	1.95e-05	0.000312	CbGpPWpGaD
Everolimus—MTOR—Disease—ADAM17—liver cancer	1.95e-05	0.000311	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB4—AKT1—liver cancer	1.94e-05	0.000311	CbGpPWpGaD
Everolimus—MTOR—Cellular responses to stress—STAT3—liver cancer	1.94e-05	0.00031	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR—HRAS—liver cancer	1.93e-05	0.000309	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR in Cancer—HRAS—liver cancer	1.91e-05	0.000306	CbGpPWpGaD
Everolimus—MTOR—Signaling by PDGF—HRAS—liver cancer	1.9e-05	0.000305	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—MAPK14—liver cancer	1.89e-05	0.000302	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—FST—liver cancer	1.88e-05	0.000302	CbGpPWpGaD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—PIK3CA—liver cancer	1.86e-05	0.000298	CbGpPWpGaD
Everolimus—MTOR—Insulin Signaling—AKT1—liver cancer	1.86e-05	0.000298	CbGpPWpGaD
Everolimus—MTOR—DAP12 interactions—IL6—liver cancer	1.86e-05	0.000298	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR in disease—IL6—liver cancer	1.86e-05	0.000298	CbGpPWpGaD
Everolimus—MTOR—Fc epsilon receptor (FCERI) signaling—IL6—liver cancer	1.86e-05	0.000298	CbGpPWpGaD
Everolimus—MTOR—Downstream signal transduction—AKT1—liver cancer	1.85e-05	0.000297	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR—IL6—liver cancer	1.85e-05	0.000296	CbGpPWpGaD
Everolimus—MTOR—EGF/EGFR Signaling Pathway—AKT1—liver cancer	1.85e-05	0.000296	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR—AKT1—liver cancer	1.85e-05	0.000296	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB2—AKT1—liver cancer	1.84e-05	0.000294	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR in Cancer—IL6—liver cancer	1.83e-05	0.000293	CbGpPWpGaD
Everolimus—MTOR—Disease—PSMA4—liver cancer	1.83e-05	0.000293	CbGpPWpGaD
Everolimus—MTOR—Disease—PSMD10—liver cancer	1.83e-05	0.000293	CbGpPWpGaD
Everolimus—MTOR—DAP12 signaling—AKT1—liver cancer	1.83e-05	0.000293	CbGpPWpGaD
Everolimus—MTOR—Signaling by PDGF—IL6—liver cancer	1.82e-05	0.000292	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—STAT3—liver cancer	1.82e-05	0.000291	CbGpPWpGaD
Everolimus—MTOR—B Cell Activation—HRAS—liver cancer	1.8e-05	0.000289	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—AKT1—liver cancer	1.8e-05	0.000288	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—TRIO—liver cancer	1.8e-05	0.000288	CbGpPWpGaD
Everolimus—CYP3A4—Biological oxidations—GSTP1—liver cancer	1.79e-05	0.000287	CbGpPWpGaD
Everolimus—MTOR—Disease—GOT2—liver cancer	1.78e-05	0.000285	CbGpPWpGaD
Everolimus—CYP3A4—Metapathway biotransformation—GSTP1—liver cancer	1.77e-05	0.000283	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—PRKCE—liver cancer	1.76e-05	0.000283	CbGpPWpGaD
Everolimus—MTOR—Immune System—IFNA1—liver cancer	1.74e-05	0.000278	CbGpPWpGaD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—HRAS—liver cancer	1.72e-05	0.000276	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CCR4—liver cancer	1.72e-05	0.000276	CbGpPWpGaD
Everolimus—MTOR—DAP12 interactions—AKT1—liver cancer	1.72e-05	0.000275	CbGpPWpGaD
Everolimus—MTOR—Fc epsilon receptor (FCERI) signaling—AKT1—liver cancer	1.72e-05	0.000275	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR in disease—AKT1—liver cancer	1.72e-05	0.000275	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR—AKT1—liver cancer	1.7e-05	0.000273	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR in Cancer—AKT1—liver cancer	1.69e-05	0.00027	CbGpPWpGaD
Everolimus—MTOR—Signaling by PDGF—AKT1—liver cancer	1.68e-05	0.000269	CbGpPWpGaD
Everolimus—FKBP1A—Disease—APC—liver cancer	1.67e-05	0.000268	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—IGF2—liver cancer	1.67e-05	0.000268	CbGpPWpGaD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—IL6—liver cancer	1.65e-05	0.000264	CbGpPWpGaD
Everolimus—CYP3A4—Biological oxidations—GSTM1—liver cancer	1.65e-05	0.000264	CbGpPWpGaD
Everolimus—CYP3A4—Metapathway biotransformation—GSTM1—liver cancer	1.62e-05	0.00026	CbGpPWpGaD
Everolimus—MTOR—B Cell Activation—AKT1—liver cancer	1.59e-05	0.000255	CbGpPWpGaD
Everolimus—FKBP1A—Disease—BRAF—liver cancer	1.57e-05	0.000252	CbGpPWpGaD
Everolimus—CYP3A4—Biological oxidations—CYP1A1—liver cancer	1.56e-05	0.00025	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—CSF2—liver cancer	1.56e-05	0.00025	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—KRAS—liver cancer	1.56e-05	0.00025	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—CDH1—liver cancer	1.55e-05	0.000248	CbGpPWpGaD
Everolimus—CYP3A4—Metapathway biotransformation—CYP1A1—liver cancer	1.54e-05	0.000247	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—PIK3CD—liver cancer	1.54e-05	0.000246	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—H2AFX—liver cancer	1.54e-05	0.000246	CbGpPWpGaD
Everolimus—MTOR—Disease—GOT1—liver cancer	1.54e-05	0.000246	CbGpPWpGaD
Everolimus—MTOR—Immune System—PRKCE—liver cancer	1.54e-05	0.000246	CbGpPWpGaD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—AKT1—liver cancer	1.52e-05	0.000244	CbGpPWpGaD
Everolimus—MTOR—Cellular responses to stress—TP53—liver cancer	1.48e-05	0.000237	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—PIK3CD—liver cancer	1.48e-05	0.000237	CbGpPWpGaD
Everolimus—FKBP1A—Disease—PIK3CD—liver cancer	1.47e-05	0.000236	CbGpPWpGaD
Everolimus—MTOR—Immune System—ABL1—liver cancer	1.46e-05	0.000234	CbGpPWpGaD
Everolimus—FKBP1A—Disease—SERPINE1—liver cancer	1.46e-05	0.000233	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—PIK3CA—liver cancer	1.43e-05	0.00023	CbGpPWpGaD
Everolimus—MTOR—Disease—PRKCE—liver cancer	1.42e-05	0.000227	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—TERT—liver cancer	1.39e-05	0.000223	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—RAF1—liver cancer	1.37e-05	0.00022	CbGpPWpGaD
Everolimus—MTOR—Immune System—HGF—liver cancer	1.37e-05	0.00022	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—ADAM17—liver cancer	1.36e-05	0.000218	CbGpPWpGaD
Everolimus—MTOR—Immune System—CSF2—liver cancer	1.36e-05	0.000217	CbGpPWpGaD
Everolimus—MTOR—Immune System—CD8A—liver cancer	1.36e-05	0.000217	CbGpPWpGaD
Everolimus—MTOR—Cellular responses to stress—IL6—liver cancer	1.35e-05	0.000217	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—PIK3CB—liver cancer	1.34e-05	0.000215	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—HRAS—liver cancer	1.33e-05	0.000212	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—RAF1—liver cancer	1.32e-05	0.000211	CbGpPWpGaD
Everolimus—FKBP1A—Disease—RAF1—liver cancer	1.31e-05	0.00021	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—PIK3CB—liver cancer	1.29e-05	0.000206	CbGpPWpGaD
Everolimus—FKBP1A—Disease—MTOR—liver cancer	1.28e-05	0.000205	CbGpPWpGaD
Everolimus—FKBP1A—Disease—PIK3CB—liver cancer	1.28e-05	0.000205	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—PSMA4—liver cancer	1.28e-05	0.000205	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—PSMD10—liver cancer	1.28e-05	0.000205	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—KDR—liver cancer	1.27e-05	0.000204	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—IL6—liver cancer	1.27e-05	0.000203	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—MAPK14—liver cancer	1.26e-05	0.000202	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—CDKN1B—liver cancer	1.26e-05	0.000202	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—ESR1—liver cancer	1.24e-05	0.000199	CbGpPWpGaD
Everolimus—MTOR—Disease—H2AFX—liver cancer	1.24e-05	0.000198	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—F2—liver cancer	1.23e-05	0.000196	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—CDKN1B—liver cancer	1.21e-05	0.000194	CbGpPWpGaD
Everolimus—FKBP1A—Disease—CDKN1B—liver cancer	1.2e-05	0.000193	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—JUN—liver cancer	1.2e-05	0.000192	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—CTNNB1—liver cancer	1.19e-05	0.00019	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—PIK3CG—liver cancer	1.17e-05	0.000188	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—APC—liver cancer	1.17e-05	0.000188	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—AKT1—liver cancer	1.17e-05	0.000188	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—UGDH—liver cancer	1.17e-05	0.000187	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—CDKN1A—liver cancer	1.16e-05	0.000186	CbGpPWpGaD
Everolimus—MTOR—Immune System—BCL2L1—liver cancer	1.16e-05	0.000186	CbGpPWpGaD
Everolimus—FKBP1A—Disease—CTNNB1—liver cancer	1.14e-05	0.000182	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—MAPK8—liver cancer	1.13e-05	0.000182	CbGpPWpGaD
Everolimus—MTOR—Disease—MTHFR—liver cancer	1.12e-05	0.000179	CbGpPWpGaD
Everolimus—MTOR—Disease—TERT—liver cancer	1.12e-05	0.000179	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—CDKN1A—liver cancer	1.12e-05	0.000179	CbGpPWpGaD
Everolimus—FKBP1A—Disease—CDKN1A—liver cancer	1.11e-05	0.000178	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—BRAF—liver cancer	1.1e-05	0.000176	CbGpPWpGaD
Everolimus—MTOR—Immune System—MAPK14—liver cancer	1.1e-05	0.000176	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—EPT1—liver cancer	1.1e-05	0.000176	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—TAT—liver cancer	1.04e-05	0.000167	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—PIK3CD—liver cancer	1.03e-05	0.000165	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—SERPINE1—liver cancer	1.02e-05	0.000163	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—PRKCE—liver cancer	9.92e-06	0.000159	CbGpPWpGaD
Everolimus—FKBP1A—Disease—STAT3—liver cancer	9.91e-06	0.000159	CbGpPWpGaD
Everolimus—MTOR—Disease—APC—liver cancer	9.42e-06	0.000151	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—IGF2—liver cancer	9.4e-06	0.000151	CbGpPWpGaD
Everolimus—MTOR—Immune System—CDH1—liver cancer	9.39e-06	0.00015	CbGpPWpGaD
Everolimus—FKBP1A—Disease—MYC—liver cancer	9.21e-06	0.000147	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—RAF1—liver cancer	9.2e-06	0.000147	CbGpPWpGaD
Everolimus—FKBP1A—Disease—TGFB1—liver cancer	9.19e-06	0.000147	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—PIK3CB—liver cancer	8.98e-06	0.000144	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—MTOR—liver cancer	8.98e-06	0.000144	CbGpPWpGaD
Everolimus—MTOR—Immune System—PIK3CD—liver cancer	8.97e-06	0.000144	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—KRAS—liver cancer	8.9e-06	0.000143	CbGpPWpGaD
Everolimus—MTOR—Disease—BRAF—liver cancer	8.85e-06	0.000142	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CSF2—liver cancer	8.78e-06	0.000141	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—H2AFX—liver cancer	8.65e-06	0.000139	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—KRAS—liver cancer	8.55e-06	0.000137	CbGpPWpGaD
Everolimus—FKBP1A—Disease—KRAS—liver cancer	8.51e-06	0.000136	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—CDKN1B—liver cancer	8.43e-06	0.000135	CbGpPWpGaD
Everolimus—MTOR—Disease—PIK3CD—liver cancer	8.28e-06	0.000133	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—CASP3—liver cancer	8.26e-06	0.000132	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—IL2—liver cancer	8.25e-06	0.000132	CbGpPWpGaD
Everolimus—MTOR—Disease—SERPINE1—liver cancer	8.19e-06	0.000131	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—PIK3CA—liver cancer	8.18e-06	0.000131	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—CCND1—liver cancer	8.04e-06	0.000129	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—JUN—liver cancer	8.03e-06	0.000128	CbGpPWpGaD
Everolimus—MTOR—Immune System—RAF1—liver cancer	8e-06	0.000128	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—CTNNB1—liver cancer	7.96e-06	0.000128	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—PIK3CA—liver cancer	7.85e-06	0.000126	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—TERT—liver cancer	7.83e-06	0.000125	CbGpPWpGaD
Everolimus—FKBP1A—Disease—PIK3CA—liver cancer	7.82e-06	0.000125	CbGpPWpGaD
Everolimus—MTOR—Immune System—PIK3CB—liver cancer	7.81e-06	0.000125	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—MMP9—liver cancer	7.81e-06	0.000125	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—CDKN1A—liver cancer	7.78e-06	0.000125	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—MAPK8—liver cancer	7.59e-06	0.000122	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—HRAS—liver cancer	7.57e-06	0.000121	CbGpPWpGaD
Everolimus—MTOR—Disease—RAF1—liver cancer	7.39e-06	0.000118	CbGpPWpGaD
Everolimus—MTOR—Immune System—CDKN1B—liver cancer	7.33e-06	0.000117	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—HRAS—liver cancer	7.27e-06	0.000116	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—IL6—liver cancer	7.24e-06	0.000116	CbGpPWpGaD
Everolimus—FKBP1A—Disease—HRAS—liver cancer	7.24e-06	0.000116	CbGpPWpGaD
Everolimus—MTOR—Disease—PIK3CB—liver cancer	7.21e-06	0.000116	CbGpPWpGaD
Everolimus—MTOR—Immune System—IL2—liver cancer	7.18e-06	0.000115	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—KDR—liver cancer	7.16e-06	0.000115	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—MAPK14—liver cancer	7.11e-06	0.000114	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—GLUL—liver cancer	7.08e-06	0.000113	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—CPT1B—liver cancer	7.08e-06	0.000113	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—VEGFA—liver cancer	7.01e-06	0.000112	CbGpPWpGaD
Everolimus—MTOR—Immune System—JUN—liver cancer	6.98e-06	0.000112	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—ESR1—liver cancer	6.98e-06	0.000112	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—STAT3—liver cancer	6.94e-06	0.000111	CbGpPWpGaD
Everolimus—MTOR—Immune System—CTNNB1—liver cancer	6.93e-06	0.000111	CbGpPWpGaD
Everolimus—FKBP1A—Disease—IL6—liver cancer	6.92e-06	0.000111	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—F2—liver cancer	6.89e-06	0.00011	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—NR1H4—liver cancer	6.82e-06	0.000109	CbGpPWpGaD
Everolimus—MTOR—Disease—CDKN1B—liver cancer	6.77e-06	0.000108	CbGpPWpGaD
Everolimus—MTOR—Immune System—CDKN1A—liver cancer	6.77e-06	0.000108	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—GSTA3—liver cancer	6.71e-06	0.000107	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—AKT1—liver cancer	6.68e-06	0.000107	CbGpPWpGaD
Everolimus—MTOR—Immune System—MAPK8—liver cancer	6.61e-06	0.000106	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—APC—liver cancer	6.59e-06	0.000106	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—PIK3CG—liver cancer	6.59e-06	0.000106	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—MYC—liver cancer	6.45e-06	0.000103	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—TGFB1—liver cancer	6.44e-06	0.000103	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—AKT1—liver cancer	6.42e-06	0.000103	CbGpPWpGaD
Everolimus—MTOR—Disease—CTNNB1—liver cancer	6.4e-06	0.000102	CbGpPWpGaD
Everolimus—FKBP1A—Disease—AKT1—liver cancer	6.39e-06	0.000102	CbGpPWpGaD
Everolimus—MTOR—Disease—CDKN1A—liver cancer	6.25e-06	0.0001	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—BRAF—liver cancer	6.2e-06	9.92e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—GSTA4—liver cancer	6.13e-06	9.82e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—STAT3—liver cancer	6.04e-06	9.67e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—GSTA2—liver cancer	5.98e-06	9.57e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—KRAS—liver cancer	5.96e-06	9.54e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—PIK3CD—liver cancer	5.8e-06	9.28e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—GSTA1—liver cancer	5.77e-06	9.23e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—SERPINE1—liver cancer	5.73e-06	9.18e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—NAT2—liver cancer	5.7e-06	9.13e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—STAT3—liver cancer	5.58e-06	8.93e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—PIK3CA—liver cancer	5.48e-06	8.77e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—ALDOB—liver cancer	5.47e-06	8.75e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—TP53—liver cancer	5.3e-06	8.48e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—CRABP1—liver cancer	5.22e-06	8.35e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—KRAS—liver cancer	5.18e-06	8.3e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—MYC—liver cancer	5.18e-06	8.29e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—RAF1—liver cancer	5.17e-06	8.28e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—TGFB1—liver cancer	5.17e-06	8.27e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—HRAS—liver cancer	5.07e-06	8.11e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—PIK3CB—liver cancer	5.05e-06	8.09e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—IL6—liver cancer	4.85e-06	7.76e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—KRAS—liver cancer	4.79e-06	7.66e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—PIK3CA—liver cancer	4.76e-06	7.63e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CDKN1B—liver cancer	4.74e-06	7.59e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CASP3—liver cancer	4.65e-06	7.44e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—IL2—liver cancer	4.64e-06	7.43e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—HPGDS—liver cancer	4.56e-06	7.3e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CCND1—liver cancer	4.52e-06	7.24e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—JUN—liver cancer	4.51e-06	7.23e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CTNNB1—liver cancer	4.48e-06	7.17e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—AKT1—liver cancer	4.47e-06	7.16e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—HRAS—liver cancer	4.41e-06	7.06e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—PIK3CA—liver cancer	4.4e-06	7.04e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—MMP9—liver cancer	4.39e-06	7.03e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CDKN1A—liver cancer	4.38e-06	7e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—MAPK8—liver cancer	4.27e-06	6.84e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—IL6—liver cancer	4.22e-06	6.75e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—HRAS—liver cancer	4.07e-06	6.51e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PSMD10—liver cancer	4.06e-06	6.51e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PSMA4—liver cancer	4.06e-06	6.51e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—GOT2—liver cancer	3.95e-06	6.33e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—VEGFA—liver cancer	3.94e-06	6.31e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—STAT3—liver cancer	3.9e-06	6.25e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—IL6—liver cancer	3.89e-06	6.23e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—AKT1—liver cancer	3.89e-06	6.23e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—CYP2E1—liver cancer	3.72e-06	5.95e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—MYC—liver cancer	3.63e-06	5.81e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—TGFB1—liver cancer	3.62e-06	5.79e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—AKT1—liver cancer	3.59e-06	5.75e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—CYCS—liver cancer	3.48e-06	5.57e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—GGT1—liver cancer	3.41e-06	5.46e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—GOT1—liver cancer	3.41e-06	5.46e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—KRAS—liver cancer	3.35e-06	5.37e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—PIK3CA—liver cancer	3.08e-06	4.93e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—GSTP1—liver cancer	3.07e-06	4.91e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—HMOX1—liver cancer	3.02e-06	4.84e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—TP53—liver cancer	2.98e-06	4.77e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—HRAS—liver cancer	2.85e-06	4.56e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—GSTM1—liver cancer	2.82e-06	4.51e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—IL6—liver cancer	2.73e-06	4.37e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—CYP1A1—liver cancer	2.67e-06	4.27e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—AKT1—liver cancer	2.52e-06	4.03e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—MTHFR—liver cancer	2.49e-06	3.99e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PPARA—liver cancer	2.44e-06	3.91e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PIK3CG—liver cancer	2.09e-06	3.35e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PPARG—liver cancer	2.02e-06	3.23e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PIK3CD—liver cancer	1.84e-06	2.94e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—ALB—liver cancer	1.82e-06	2.91e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PIK3CB—liver cancer	1.6e-06	2.57e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PIK3CA—liver cancer	9.77e-07	1.56e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—AKT1—liver cancer	7.98e-07	1.28e-05	CbGpPWpGaD
